Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12
| Författare |
Stephanie Haller Josefine Reber Simone Brandt Peter Bernhardt Viola Groehn Roger Schibli Cristina Müller |
|---|---|
| Publicerad i | Nuclear medicine and biology |
| Volym | 42 |
| Nummer/häfte | 10 |
| Sidor | 770-9 |
| ISSN | 1872-9614 |
| Publiceringsår | 2015 |
| Publicerad vid |
Institutionen för kliniska vetenskaper, Avdelningen för radiofysik |
| Sidor | 770-9 |
| Språk | en |
| Länkar |
dx.doi.org/10.1016/j.nucmedbio.2015... |
| Ämnesord | Radionuclide therapy; 177Lu; Radiofolates; Albumin-binder; Radionephropathy; Kidney damage |
| Ämneskategorier | Radiofysik |
Application of therapeutic folate radioconjugates is a promising option for the treatment of folate receptor (FR)-positive tumors, although high uptake of radiofolates in the kidneys remains a critical issue. Recently, it was shown that enhancing the blood circulation of radiofolates results in increased tumor uptake and reduced retention of radioactivity in the kidneys. In this study, we investigated and compared the anti-tumor effects and potential long-term damage to the kidneys after application of an albumin-binding ((177)Lu-cm09), and a conventional ((177)Lu-EC0800) folate radioconjugate.
GÖTEBORGS UNIVERSITET • Box 100 • 405 30 Göteborg • Telefon: 031 786 0000
Kontakt • Organisationsnummer: 202100-3153 • Om webbplatsen
Facebook
Twitter
Instagram
Snapchat
Youtube